Cargando…

Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits

BACKGROUND: Opioids are not recommended for routine treatment of migraine because their benefits are outweighed by risks of medication overuse headache and abuse/dependence. A March 2016 US Food and Drug Administration (FDA) safety communication warned of the risk of serotonin syndrome from using op...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molina, Kyle C, Fairman, Kathleen A, Sclar, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937481/ https://www.ncbi.nlm.nih.gov/pubmed/29760569 http://dx.doi.org/10.2147/DHPS.S151073

Ejemplares similares

Cardiovascular Risk Factors and Provision of Lifestyle Counseling for Diabetes or Prediabetes With Comorbid Obesity: Analysis of Office-Based Physician Visits Made by Patients 20 Years of Age or Older
por: Karr, Samantha, et al.
Publicado: (2019)

Codeine Precipitating Serotonin Syndrome in a Patient in Therapy with Antidepressant and Triptan
por: Milano, Giulia, et al.
Publicado: (2017)

Maternal Serotonergic Antidepressant Use in Pregnancy and Risk of Seizures in Children
por: Wiggs, Kelsey Kathleen, et al.
Publicado: (2022)

Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?
por: Fairman, Kathleen A., et al.
Publicado: (2018)

Different characteristics of triptans
por: Pini, Luigi A., et al.
Publicado: (2004)

Serotonergic Antidepressants and Risk for Traumatic Intracranial Bleeding
por: Isokuortti, Harri, et al.
Publicado: (2021)

All triptans are not the same
por: Rapoport, Alan M., et al.
Publicado: (2001)

Clinical experience with triptans
por: Zanchin, Giorgio, et al.
Publicado: (2001)

Success and failure of triptans
por: Saxena, Pramod R., et al.
Publicado: (2001)

Selecting the preferred triptans
por: McCrory, Douglas C., et al.
Publicado: (2004)

Costs and Utilization of Triptan Users Who Receive Drug Prophylaxis for Migraine Versus Triptan Users Who Do Not Receive Drug Prophylaxis
por: Etemad, Lida R., et al.
Publicado: (2005)

The role of serotonergic and catecholaminergic systems for possible antidepressant activity of apigenin
por: Al-Yamani, Mohammad J., et al.
Publicado: (2022)

Do Triptan Antimigraine Medications Interact with SSRI/SNRI Antidepressants? What Does Your Decision Support System Say?
por: Kogut, Stephen J.
Publicado: (2011)

The medicalization of sleeplessness: Results of U.S. office visit outcomes, 2008–2015
por: Moloney, Mairead Eastin, et al.
Publicado: (2019)

Collaborative practice trends in US physician office visits: an analysis of the National Ambulatory Medical Care Survey (NAMCS), 2007–2016
por: Najmabadi, Shahpar, et al.
Publicado: (2020)

Best Value for Money in Triptans
por: Curtiss, Frederic R.
Publicado: (2005)

The antidepressant-like effect of trans-astaxanthin involves the serotonergic system
por: Jiang, Xi, et al.
Publicado: (2017)

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient–Physician Visits
por: Rubin, David T., et al.
Publicado: (2017)

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
por: Fairman, Kathleen A, et al.
Publicado: (2017)

Switching Antidepressant Drug Therapy Helps Some Patients Some of the Time--What TORDIA, STAR*D, and Observational Research Have Taught Us About Treatment-Resistant Depression
por: Curtiss, Frederic R., et al.
Publicado: (2008)

Joint effects of advancing age and number of potentially inappropriate medication classes on risk of falls in Medicare enrollees
por: Early, Nicole K., et al.
Publicado: (2019)

Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance
por: Peckham, Alyssa M, et al.
Publicado: (2018)

Triptans and troponin: a case report
por: Weder, Claudia R, et al.
Publicado: (2009)

Multiple Chronic Conditions Among US Adults Who Visited Physician Offices: Data From the National Ambulatory Medical Care Survey, 2009
por: Ashman, Jill Jacobsen, et al.
Publicado: (2013)

Antidepressant activity of rose oxide essential oil: possible involvement of serotonergic transmission
por: Matias Nascimento Maia, Wcleubianne, et al.
Publicado: (2021)

The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication
por: Andrashko, Veronika, et al.
Publicado: (2020)

Use of power-law analysis to predict abuse or diversion of prescribed medications: proof-of-concept mathematical exploration
por: Fairman, Kathleen A., et al.
Publicado: (2018)

The Impact of Pediatric Opioid-Related Visits on U.S. Emergency Departments
por: Champagne-Langabeer, Tiffany, et al.
Publicado: (2022)

Use of triptans for the control of headache in bacterial meningitis
por: Wiwanitkit, Viroj
Publicado: (2014)

Stroke, Migraine and Triptans: From Bedside to Bench
por: Raschi, Emanuel, et al.
Publicado: (2016)

Triptans and CGRP blockade – impact on the cranial vasculature
por: Benemei, Silvia, et al.
Publicado: (2017)

Regular physical activity prevents development of chronic muscle pain through modulation of supraspinal opioid and serotonergic mechanisms
por: Brito, Renan G., et al.
Publicado: (2017)

Visit of Asmeret Asefaw Berhe, Director of the Office of Science at the US Department of Energy
por: Fichet, Jacques Herve
Publicado: (2022)

Impact of air pollution on physician office visits for common childhood conditions in Ontario, Canada
por: Feldman, Laura, et al.
Publicado: (2014)

Computational and biological evidences on the serotonergic involvement of SeTACN antidepressant-like effect in mice
por: Fronza, Mariana G., et al.
Publicado: (2017)

Participation of the Serotonergic System and Brain-Derived Neurotrophic Factor in the Antidepressant-like Effect of Flavonoids
por: German-Ponciano, León Jesús, et al.
Publicado: (2022)

Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants
por: Ben-Sheetrit, Joseph, et al.
Publicado: (2023)

Risk of respiratory depression with opioids and concomitant gabapentinoids
por: Savelloni, Julie, et al.
Publicado: (2017)

Association of Serotonergic Pathway Gene Polymorphisms With Behavioral Parameters in Patients With Opioid Dependence
por: Sarkar, Siddharth, et al.
Publicado: (2021)

Triptans in clinical practice: the basic scientist’s point of view
por: Buzzi, M. Gabriella
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_ru9q8l2erhu902thg26utqu82u